Genmab A/S (0MGB.IL)
Develops antibody drugs that train the immune system to attack cancer and other diseases
1,878.25-0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+35.3%
The outlook
Genmab is trading above both its 50- and 200-day moving averages, positioning it in the middle-to-upper portion of its 52-week range. Analyst sentiment leans bullish overall, though the stock carries a trailing P/E of 26.5, reflecting elevated valuation relative to current earnings.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range59% of the way from its 52-week low to high
Market cap
$150.41B
52-wk high
2,256.00
52-wk low
1,337.00
50-day avg
1,743.59
200-day avg
1,857.39
Trailing P/E
26.5